Business
Update on contingency planning for no-deal Brexit
Update on contingency planning for no-deal Brexit.
About this update from Surgical Innovations Group Plc
[{"type":"text","content":"\n \nRNS Number : 5357Q Surgical Innovations Group PLC 20 February 2019 \n\nSurgical Innovations Group plc\n(\"Surgical Innovations\" or \"the Company\")\n \nUpdate on contingency planning for no-deal Brexit\n \nSurgical Innovations (AIM: SUN), the designer and manufacturer of innovative technology for minimally invasive surgery, provides an update on contingency planning for the possibility of the U.K. leaving the EU without an appropriate Withdrawal Agreement. \n \nOn 15 February 2019, BSI Netherlands confirmed the successful reassignment of all of the Company's product certification from BSI Notified Body 0086 (U.K.) to the Netherlands Notified Body 2797. \n \nNigel Rogers, Executive Chairman of SI Group, stated: \"Amidst speculation in the weekend press of possible disruption to the approvals status of medical devices across the EU following a no-deal Brexit, it is reassuring that we have taken this important precaution. Our first priority is to protect the integrity of our regulatory approvals for the EU market, and this will serve to reassure our distribution partners and end users of continuity in coming months.\"\n \nFor further information contact: \n \n\n\n\nSurgical Innovations Group Plc\n\n\nwww.sigroupplc.com\n\n\n\n\nNigel Rogers, Executive Chairman \n\n\nTel: +44 (0)113 230 7597\n\n\n\n\nMelanie Ross, COO and CFO\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR (Financial PR & Investor Relations)\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus\n\n\nMob: +44 (0)7980 541 893\n\n\n\n\nLianne Cawthorne\n\n\nMob: +44 (0)7584 391 303\n\n\n\n\n\n\n\n\n\n\n\n\nN+1 Singer (Nominated Adviser and Broker)\n\n\n+44 (0)20 7496 3000\n\n\n\n\nRichard Lindley\n\n\n\n\n\n\n\nRachel Hayes\n\n\n\n\n\n\n \n \n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END UPDEAPANFSENEFF\n ","length":5758,"tagName":"div"}]